- Home
- OTGA vs SLGL Comparison
OTGA vs SLGL Comparison
Compare OTGA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTGA | SLGL |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.0M | 255.2M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | OTGA | SLGL |
|---|---|---|
| Price | $10.17 | $82.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 26.1K | ★ 27.8K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.97 | $12.50 |
| 52 Week High | $10.19 | $97.97 |
Technical Indicators
Market Signals| Indicator | OTGA | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 61.31 |
| Support Level | $10.03 | $67.53 |
| Resistance Level | N/A | $95.31 |
| Average True Range (ATR) | 0.00 | 6.35 |
| MACD | -0.00 | 0.47 |
| Stochastic Oscillator | 66.67 | 70.23 |
Price Performance
Historical ComparisonAbout OTGA OTG Acquisition Corp. I Class A Ordinary Share
OTG Acquisition Corp I is a newly organized blank check company.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.